Skip to main content
TipRanks
Go Ultimate75% OFF

AlzeCure Pharma AB (ALZCUR) AI Stock Analysis

0 Followers
SE:ALZCUR

AlzeCure Pharma AB

(Nasdaq OMX AB:ALZCUR)

Select Model
Rating:50Neutral
Price Target:SEK 6.50â–²(1.56% Upside)
Action:reiterated
Date:08/28/26

The score is held down primarily by weak financial performance (no revenue, large losses, and substantial ongoing cash burn with declining equity), implying continued funding dependence. Technicals are a supportive offset with the stock above major moving averages and non-overbought momentum, while valuation is less supportive due to a high P/E and no dividend yield data.

Positive Factors
Low leverageThe company has comparatively low financial leverage, which limits interest and refinancing pressure relative to its equity base. This provides more balance-sheet flexibility than a highly indebted biotech and can help preserve strategic options while pipeline programs progress.
Negative Factors
No commercial revenueZero reported revenue means the company has not yet established a commercial income stream to offset research and development spending. Until a candidate is partnered successfully or reaches approval, financial performance remains dependent on funding rather than recurring product sales.

AlzeCure Pharma AB (ALZCUR) vs. iShares MSCI Sweden ETF (EWD)

-100%0%100%200%300%400%SE:ALZCUR+254.77%EWD+15.64%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
SEK 882.54M
Dividend Yield
―
Average Volume (3M)
310.93K
Price to Earnings (P/E)
10.7
Beta (1Y)
0.33
Revenue Growth
―
EPS Growth
―
Country
Sweden
Employees
10
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

AlzeCure Pharma AB Business Overview & Revenue Model

Company Description

AlzeCure Pharma AB (publ) operates as a pharmaceutical company that develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is involved in the development of drug candidates base...

How the Company Makes Money

AlzeCure Pharma AB’s business model is typical of an early-stage biotech/pharma R&D company: it primarily creates value by discovering and developing drug candidates and then seeking to monetize them through partnering transactions and, potentially,...

AlzeCure Pharma AB Financial Statement Overview

Summary

Weak financial profile typical of a development-stage biotech: zero revenue, persistent and sizable losses (TTM net loss ~59.2M; EBIT ~-62.9M) and heavy cash burn (TTM operating cash flow/free cash flow ~-41.0M). Balance sheet leverage is low (TTM debt ~2.29M vs equity ~11.23M), but equity has fallen sharply over time, increasing financing risk.

Income Statement

12Very Negative

Balance Sheet

55Neutral

Cash Flow

20Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue66.19M00000
Gross Profit-602.00K-1.27M-293.00K-476.00K-570.00K-576.00K
EBITDA11.88M-48.10M-35.70M-37.87M-55.67M-77.20M
Net Income12.84M-47.65M-35.23M-37.17M-56.04M-77.78M
Balance Sheet
Total Assets238.60M59.04M34.44M32.00M70.84M45.65M
Cash, Cash Equivalents and Short-Term Investments231.93M50.34M31.50M29.10M25.58M41.74M
Total Debt1.72M5.12M0000
Total Liabilities20.12M26.12M8.25M8.23M10.35M12.67M
Stockholders Equity218.48M32.92M26.18M23.77M60.48M32.97M
Cash Flow
Free Cash Flow110.55M-34.59M-35.25M3.06M-99.91M-70.69M
Operating Cash Flow110.55M-34.59M-35.12M3.06M-99.91M-70.64M
Investing Cash Flow00-124.00K7,0000-54.00K
Financing Cash Flow73.43M53.43M37.65M459.00K83.75M0

AlzeCure Pharma AB Technical Analysis

Technical Analysis SentimentNegative
Last Price6.40

Price Trends

50DMA7.08Negative
100DMA6.84Negative
200DMA4.30Positive

Market Momentum

MACD-0.16Negative
RSI44.17Neutral
STOCH79.65Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ALZCUR, the sentiment is Negative. The current price of 6.40 is below the 20-day moving average (MA) of 6.47, below the 50-day MA of 7.08, and above the 200-day MA of 4.30, indicating a neutral trend. The MACD of -0.16 indicates Negative momentum. The RSI at 44.17 is Neutral, neither overbought nor oversold. The STOCH value of 79.65 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:ALZCUR.

AlzeCure Pharma AB Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

SE:ALZCUR against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SE:CAMXSE:CAMX78OutperformSEK 45.12B58.6616.50%―2.96%-4.07%
SE:SANIONSE:SANION77OutperformSEK 1.64B8.8929.71%―24.98%-31.44%
SE:BIOA.BSE:BIOA.B65NeutralSEK 27.51B260.505.18%0.69%-46.09%-90.13%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SE:ALZCURSE:ALZCUR50NeutralSEK 882.54M10.67105.09%―――
SE:ALZSE:ALZ44NeutralSEK 100.82M-1.88-15.44%―-100.00%40.79%
SE:IRLAB.ASE:IRLAB.A38UnderperformSEK 126.11M-1.30-97.06%―-21.20%68.24%

* Healthcare Sector Average

Performance Comparison

0%100%200%300%SE:ALZCURSE:CAMXSE:ALZSE:BIOA.BSE:SANIONSE:IRLAB.ADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SE:ALZCUR and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SE:ALZCURAlzeCure Pharma AB6.404.54243.16%
SE:CAMXCamurus AB745.00123.0019.77%
SE:ALZAlzinova AB0.32-1.23-79.42%
SE:BIOA.BBioArctic AB Class B310.0025.498.96%
SE:SANIONSaniona AB11.91-4.31-26.57%
SE:IRLAB.AIRLAB Therapeutics AB Class A0.85-1.37-61.82%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 28, 2026